AR082418A1 - CRYSTAL FORMS OF 1- (4-METHYL-5- [2- (2,2,2-TRIFLUORO-1,1-DIMETHYL-Ethyl) -PIRIDIN-4-IL] -TIAZOL-2-IL) -AMIDE OF 2 -AMIDA OF THE ACID (S) -PIRROLIDIN-1,2-DICARBOXILICO - Google Patents

CRYSTAL FORMS OF 1- (4-METHYL-5- [2- (2,2,2-TRIFLUORO-1,1-DIMETHYL-Ethyl) -PIRIDIN-4-IL] -TIAZOL-2-IL) -AMIDE OF 2 -AMIDA OF THE ACID (S) -PIRROLIDIN-1,2-DICARBOXILICO

Info

Publication number
AR082418A1
AR082418A1 ARP110102747A ARP110102747A AR082418A1 AR 082418 A1 AR082418 A1 AR 082418A1 AR P110102747 A ARP110102747 A AR P110102747A AR P110102747 A ARP110102747 A AR P110102747A AR 082418 A1 AR082418 A1 AR 082418A1
Authority
AR
Argentina
Prior art keywords
trifluoro
amide
dimethyl
ethyl
methyl
Prior art date
Application number
ARP110102747A
Other languages
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR082418A1 publication Critical patent/AR082418A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

La presente se refiere a formas sólidas específicas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il-amida de 2-amida del ácido (S)-pirrolidin-1,2-dicarboxílico, y sus hidratos y solvatos. La presente se refiere además a procesos para la preparación de estas formas sólidas, a composiciones farmacéuticas que comprenden tales formas sólidas, y a métodos para utilizar las formas sólidas mencionadas y composiciones farmacéuticas para tratar enfermedades.Reivindicación 1: Una forma cristalina del compuesto de la fórmula (1) o un hidrato o solvato de la forma cristalina del compuesto de la fórmula (1).This refers to specific solid forms of 1- (4-methyl-5- [2- (2,2,2-trifluoro-1,1-dimethyl-ethyl) -pyridin-4-yl] -thiazol-2- (S) -Pyrrolidin-1,2-dicarboxylic acid 2-amide, and its hydrates and solvates, also relates to processes for the preparation of these solid forms, to pharmaceutical compositions comprising such solid forms and to methods for using the solid forms mentioned and pharmaceutical compositions for treating diseases. Claim 1: A crystalline form of the compound of the formula (1) or a hydrate or solvate of the crystalline form of the compound of the formula (1).

ARP110102747A 2010-08-02 2011-07-29 CRYSTAL FORMS OF 1- (4-METHYL-5- [2- (2,2,2-TRIFLUORO-1,1-DIMETHYL-Ethyl) -PIRIDIN-4-IL] -TIAZOL-2-IL) -AMIDE OF 2 -AMIDA OF THE ACID (S) -PIRROLIDIN-1,2-DICARBOXILICO AR082418A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36983710P 2010-08-02 2010-08-02

Publications (1)

Publication Number Publication Date
AR082418A1 true AR082418A1 (en) 2012-12-05

Family

ID=44503814

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102747A AR082418A1 (en) 2010-08-02 2011-07-29 CRYSTAL FORMS OF 1- (4-METHYL-5- [2- (2,2,2-TRIFLUORO-1,1-DIMETHYL-Ethyl) -PIRIDIN-4-IL] -TIAZOL-2-IL) -AMIDE OF 2 -AMIDA OF THE ACID (S) -PIRROLIDIN-1,2-DICARBOXILICO

Country Status (3)

Country Link
AR (1) AR082418A1 (en)
TW (1) TW201206922A (en)
WO (1) WO2012016970A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2839621A1 (en) * 2011-06-21 2012-12-27 Novartis Ag Polymorphs of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide
BR112014023530A2 (en) 2012-03-29 2017-07-18 Novartis Ag pharmaceutical diagnosis
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
WO2014191938A1 (en) * 2013-05-31 2014-12-04 Novartis Ag Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer
PL3200772T3 (en) * 2014-10-03 2022-12-19 Novartis Ag Pharmaceutical compositions comprising alpelisib

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (en) 1976-09-06 1985-09-13 喜徳 喜谷 Cis platinum(2) complex of 1,2-diaminocyclohexane isomer
US4323581A (en) 1978-07-31 1982-04-06 Johnson & Johnson Method of treating carcinogenesis
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
EP0303697B1 (en) 1987-03-09 1997-10-01 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance k-252
US4904768A (en) 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
JP2766360B2 (en) 1988-02-04 1998-06-18 協和醗酵工業株式会社 Staurosporine derivative
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
WO1993007153A1 (en) 1991-10-10 1993-04-15 Schering Corporation 4'-(n-substituted-n-oxide)staurosporine derivatives
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
JPH07505124A (en) 1991-11-08 1995-06-08 ザ ユニバーシティ オブ サザン カリフォルニア Composition containing K-252 compound for enhancing neurotrophin activity
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5948898A (en) 1992-03-16 1999-09-07 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5756494A (en) 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
ES2225824T3 (en) 1992-08-31 2005-03-16 Ludwig Institute For Cancer Research ISOLATED NONAPEPTIDE DERIVED FROM GEN MAGE-3 AND PRESENTED BY HLA-A1, AND ITS USES.
WO1994006799A1 (en) 1992-09-21 1994-03-31 Kyowa Hakko Kogyo Co., Ltd. Thrombocytopenia remedy
ES2173873T5 (en) 1992-10-28 2007-03-01 Genentech, Inc. USE OF ANTI-VEGF ANTIBODIES FOR CANCER TREATMENT.
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
CZ288182B6 (en) 1993-07-15 2001-05-16 Minnesota Mining & Mfg Imidazo[4,5-c]pyridine-4-amines and pharmaceutical preparations based thereon
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
JP3998261B2 (en) 1993-12-23 2007-10-24 イーライ・リリー・アンド・カンパニー Protein kinase C inhibitor
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
DK0817775T3 (en) 1995-03-30 2001-11-19 Pfizer quinazoline
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
WO1997007081A2 (en) 1995-08-11 1997-02-27 Yale University Glycosylated indolocarbazole synthesis
FR2741881B1 (en) 1995-12-01 1999-07-30 Centre Nat Rech Scient NOVEL PURINE DERIVATIVES HAVING IN PARTICULAR ANTI-PROLIFERATIVE PRORIETES AND THEIR BIOLOGICAL APPLICATIONS
CA2231105C (en) 1995-12-08 2005-09-13 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
KR100447918B1 (en) 1996-07-25 2005-09-28 동아제약주식회사 Flavones and flavanone compounds with protective gastrointestinal tract including large intestine
WO1998005769A2 (en) 1996-08-02 1998-02-12 Genesense Technologies, Inc. Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
CO4950519A1 (en) 1997-02-13 2000-09-01 Novartis Ag PHTHALAZINES, PHARMACEUTICAL PREPARATIONS THAT UNDERSTAND THEM AND THE PROCESS FOR THEIR PREPARATION
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
EP1017394B1 (en) 1997-07-12 2005-12-07 Cancer Research Technology Limited Cyclin dependent kinase inhibiting purine derivatives
RS49779B (en) 1998-01-12 2008-06-05 Glaxo Group Limited, Byciclic heteroaromatic compounds as protein tyrosine kinase inhibitors
CA2314156C (en) 1998-05-29 2010-05-25 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
US20030083242A1 (en) 1998-11-06 2003-05-01 Alphonse Galdes Methods and compositions for treating or preventing peripheral neuropathies
CA2727172A1 (en) 1999-05-26 2001-01-04 Genentech, Inc. Methods of treatment using anti-erbb antibody-maytansinoid conjugates
AU6014900A (en) 1999-07-13 2001-01-30 Kyowa Hakko Kogyo Co. Ltd. Staurosporin derivatives
BR0015203A (en) 1999-11-05 2002-07-16 Astrazeneca Ab Quinazoline derivative, process for the preparation of a quinazoline derivative, pharmaceutical composition, use of a compound, and, process for the production of an anti-angiogenic and / or reducing effect on vascular permeability in a warm-blooded animal
AR034118A1 (en) 2000-02-15 2004-02-04 Sugen Inc COMPOUNDS OF 2-INDOLINONES REPLACED WITH PROTEINQUINASE INHIBITING PIRROLS; YOUR PHARMACEUTICAL AND INTERMEDIARY SYNTHESIS COMPOSITIONS
PT1274718E (en) 2000-04-12 2007-01-31 Genaera Corp A process for the preparation of 7.alpha.-hydroxy 3-aminosubstituted sterols using intermediates with an unprotected 7.alpha.-hydroxy group
NZ522989A (en) 2000-06-30 2005-06-24 Glaxo Group Ltd Quinazoline ditosylate salt compounds
EP1317442B1 (en) 2000-09-11 2005-11-16 Chiron Corporation Quinolinone derivatives as tyrosine kinase inhibitors
US6677450B2 (en) 2000-10-06 2004-01-13 Bristol-Myers Squibb Company Topoisomerase inhibitors
AU2002245272B2 (en) 2001-01-16 2006-06-29 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
WO2002062826A1 (en) 2001-02-07 2002-08-15 Vadim Viktorovich Novikov Method for producing peptides
WO2003004505A1 (en) 2001-07-02 2003-01-16 Debiopharm S.A. Oxaliplatin active substance with a very low content of oxalic acid
KR100484504B1 (en) 2001-09-18 2005-04-20 학교법인 포항공과대학교 Inclusion compound comprising curcurbituril derivatives as host molecule and pharmaceutical composition comprising the same
US20030134846A1 (en) 2001-10-09 2003-07-17 Schering Corporation Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
WO2003077902A1 (en) 2002-02-19 2003-09-25 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
MXPA04009541A (en) 2002-03-29 2005-01-25 Chiron Corp Substituted benzazoles and use thereof as raf kinase inhibitors.
US6727272B1 (en) 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
US7521062B2 (en) 2002-12-27 2009-04-21 Novartis Vaccines & Diagnostics, Inc. Thiosemicarbazones as anti-virals and immunopotentiators
WO2004064759A2 (en) 2003-01-21 2004-08-05 Chiron Corporation Use of tryptanthrin compounds for immune potentiation
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
UA104147C2 (en) 2008-09-10 2014-01-10 Новартис Аг Pyrrolidine dicarboxylic acid derivative and use thereof in the treatment of proliferative diseases

Also Published As

Publication number Publication date
WO2012016970A1 (en) 2012-02-09
TW201206922A (en) 2012-02-16

Similar Documents

Publication Publication Date Title
AU2016202535B2 (en) Fused heterocyclic compounds as sodium channel modulators
IL260297A (en) Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
AU2012214029A8 (en) Rorgammat inhibitors
EA201691401A1 (en) INDASOLIC COMPOUNDS AS IRAK4 INHIBITORS
PE20150639A1 (en) CRYSTAL FORMS OF XIA FACTOR INHIBITOR
EA201490357A1 (en) INTRODUCTION
SV2008003088A (en) NEW CRYSTAL FORM VI OF AGOMELATINE, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
WO2011110876A8 (en) Novel salts for the manufacture of pharmaceutical compositions
IN2014DN05772A (en)
AR082418A1 (en) CRYSTAL FORMS OF 1- (4-METHYL-5- [2- (2,2,2-TRIFLUORO-1,1-DIMETHYL-Ethyl) -PIRIDIN-4-IL] -TIAZOL-2-IL) -AMIDE OF 2 -AMIDA OF THE ACID (S) -PIRROLIDIN-1,2-DICARBOXILICO
GEP20135882B (en) Crystal form of phenylamino pyrimidine derivatives
CO6710915A2 (en) Pharmaceutical compositions containing a dgat1 4- (4- (5-6 (- trifluoromethyl-pyridin-3-ylamino) -pyridin-2-yl) phenyl) cycloheiyl) -acetic acid inhibitor or salts thereof
HK1259405A1 (en) New crystalline form of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
BR112013029999A2 (en) thiazole derivatives
CL2011001405A1 (en) Procedure for the preparation of n- [2- (7-methoxy-1-naphthyl) ethyl] acetamide, agomethalin.
MX2021015656A (en) Amorphous and crystalline forms of ido inhibitors.
BR112012032248A2 (en) 5-ethyl-2- {4 - [- 4- (-4-tetrazol-1-yl-phenoxymethyl) -thiazol-2-yl] -piperidin-1-yl} -pyrimidine compositions
BR112013032687A2 (en) device for closed-loop control of process gases in a plant to produce directly reduced metal ores
CL2013003078A1 (en) Use of a pharmaceutical combination comprising the compound 1 - ({4-methyl-5- [2- (2,2,2-trifluoro-1,1-dimethylethyl) pyridin-4-yl] -thiazol-2-yl} -amide) of 2-amide of the pyrrolidin-1,2-dicarboxylic acid and the mtor everolimus inhibitor for treating breast cancer; and use of the pharmaceutical composition
CL2013000929A1 (en) Crystalline form c of the sodium salt of the acid (4- (4- (5- (6-trifluoro methyl pyridin-3-yl-amino) pyridin-2-yl-) phenyl) -cyclohexyl) -acetic acid; Preparation process; pharmaceutical composition that includes it; and its use for the treatment of a disorder associated with the activity of dagt.
SV2009003345A (en) NEW PROCEDURE FOR OBTAINING THE CRYSTALLINE V FORM OF AGOMELATINE
WO2014108336A8 (en) Pyrazolyl-based carboxamides ii as crac channel inhibitors
MX2015008919A (en) Pyrazolyl-based carboxamides i as crac channel inhibitors.
AR085909A1 (en) DERIVATIVES OF AZAESPIRODECANONA, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PROCEDURE TO PREPARE THEM AND USE OF THEM FOR THE TREATMENT OF DIABETES, OBESITY AND CARDIOVASCULAR DISEASES, BETWEEN OTHER
AR100095A1 (en) SOLID FORMS OF ACID {[(2R, 3S, 4R, 5S) -4- (4-CHLORO-2-FLUORO-PHENYL) -3- (3-CHLORO-2-FLUORO-PHENYL) -4-CIANO-5- (2,2-DIMETIL-PROPIL) -PIRROLIDIN-2-CARBONIL] -AMINO} -3-METOXI-BENZOICO

Legal Events

Date Code Title Description
FB Suspension of granting procedure